glp 1 receptor agonist heart failure GLP-1 Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes Frontiers | GLP-1 Receptor Agonists
Description
Strong demand for metabolic disorder therapies is expected to continue driving market progression over the forecast period
Metabolic dysfunction-associated steatotic liver disease is another prevalent metabolic comorbidity in obese women with PCOS
Stronger pharmacy involvement
Additionally, Cucurbitacin B (CuB) stimulates GLP-1 secretion via the bitter taste receptor TAS2R10 and, similar to Metformin, induces hypoglycemic effects in diabetic mice [194]
